Expert and swift publishing support for an urgent EU Marketing Authorization Application
Boyds was approached by a biotech to manage the publishing of an EU Marketing Authorization Application (MAA) Submission for a new medicinal product in a very short turn around.
Regulatory support for the development of a stem cell therapy and device for the treatment of Parkinson’s Disease
Boyds provided regulatory support to an academic institution client with an exciting proposal for a first-in-human stem cell therapy trial involving a medical device for the treatment of Parkinson’s Disease.
Providing support for a phase 2 study in patients with metastatic breast cancer in the UK and EU
Boyds provided services to assist an EU Sponsor with the set up and ongoing site management of a study in patients with advanced metastatic breast cancer in the UK and Spain.
Strategic study start-up support in the UK and Europe
Boyds was engaged to support a client in the US with study start-up services in the UK and France for a gene therapy study in patients with an ocular condition.
Combined gene therapy expertise supports US biotech
The client was an early-stage start-up in the pre-clinical stage of developing a suite of gene therapy products for a cardiovascular indication.
Expansion of oncology clinical programme into other indications
The client came to Boyds with an exciting cell therapy programme that released its active molecule selectively in solid tumour cells.
Supporting new biotech companies spinning out of academia
Boyds played an important role in the formation of academia spin-out, Axovia, by providing technical and strategic support, alongside product development plans for the company’s drug programmes.
Product development support to benchmark novel medical food product
The client, an R&D driven FMCG company, approached Boyds to help them better understand how to successfully develop and position their novel medical food product in the market.
Boyds supports acquisition of UK-based oncology drug developer with scientific due diligence
Case study: Large company investments – Boyds supports the acquisition of UK-based oncology drug developer Background: The client was a large Asian-headquartered biopharmaceutical company, looking to grow through the purchase of multiple clinical and pre-clinical acquisitions. The target company with whom they wanted to engage with was a UK-based biotech company with assets in both […]
Assessment of novel vaccine technology triggers further investment
Case study: Assessment of novel vaccine technology triggers further investment Background: The client was a large multi-national fund, who has part ownership of a small biotech with a novel platform technology. The target company with whom they wanted to engage with was a European-based biotech company who were developing a novel technology platform to facilitate the […]
